Sexual arousal disorder

Daré Bioscience Announces Subject Screening for Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder Complete

Retrieved on: 
Tuesday, November 1, 2022
Cream, Failure, Vulva, Arousal, CEO, Health, Potential, Menopause, PRO, Sex, SST, Sexual arousal disorder, SEC, GLOBE, 8-K, Health minister, Risk, COVID-19, Sexual desire, Intellectual property, Trial of the century, Fertility, Progesterone, Drug, FSAD, Organon, Safety, Vasodilation, ED, Form, NASDAQ, Social media, Investor, Review, Woman, FDA, Bacterial vaginosis, Patient, Man, Prevalence, Birth, RESPOND, Erectile dysfunction, Forward-looking statement, HSDD, Female, Vagina, Solution, Pharmaceutical industry, Sex industry, Birth control, Bayer

SAN DIEGO, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, and Strategic Science & Technologies, LLC (SST), a Cambridge, MA based novel topical drug delivery company, today announced that subject screening for the exploratory Phase 2b RESPOND clinical study of Sildenafil Cream, 3.6% is complete, allowing for a topline data announcement target of 2Q-2023. The Phase 2b RESPOND clinical study is a multi-center, double-blind, placebo-controlled study to evaluate the efficacy and safety of Sildenafil Cream, 3.6% in premenopausal patients with female sexual arousal disorder (FSAD). A total of approximately 100 subjects have completed all study assessments to date and, based on the subjects that have completed screening, a total of approximately 160 to 170 subjects are expected to complete the study for inclusion in the topline data assessment targeted for 2Q-2023.

Key Points: 
  • The Phase 2b RESPOND clinical study is a multi-center, double-blind, placebo-controlled study to evaluate the efficacy and safety of Sildenafil Cream, 3.6% in premenopausal patients with female sexual arousal disorder (FSAD).
  • Sildenafil Cream is a proprietary topical formulation of sildenafil, a phosphodiesterase-5 (PDE-5) inhibitor, being developed as a first-in-category option for the treatment of FSAD.
  • We look forward to evaluating the topline data next year, said Sabrina Martucci Johnson, President and CEO of Dar Bioscience.
  • Increasing blood flow to the genital tissue, as Sildenafil Cream is designed to do, has the potential to improve genital arousal response and overall sexual experience for women.

Daré Bioscience Announces Interim Analysis of Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder

Retrieved on: 
Monday, August 29, 2022
Cream, COVID-19, CEO, Safety, Female, Health minister, Bacterial vaginosis, SAN, SST, NASDAQ, Erectile dysfunction, Solution, Man, 8-K, ED, Vasodilation, Sex, Birth, SEC, Review, Menopause, Sexual desire, Progesterone, HSDD, GLOBE, Fertility, Prevalence, Vulva, FSAD, FDA, Arousal, Social media, PRO, RESPOND, Failure, Twitter, Form, Investor, Risk, Vagina, Organon, Intellectual property, Woman, Health, Sexual arousal disorder, Forward-looking statement, Trial of the century, Patient, Pharmaceutical industry, Sex industry, Birth control, Bayer

SAN DIEGO, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, and Strategic Science & Technologies, LLC (SST), a Cambridge, MA based novel topical drug delivery company, today announced that, based on the results of an interim analysis to evaluate the relative magnitude of the treatment effect, they expect to complete enrollment in the exploratory Phase 2b RESPOND clinical study of Sildenafil Cream, 3.6% in 4Q-2022, allowing for a topline data announcement target of 2Q-2023. The interim analysis was conducted by an independent third-party statistical resource and both Daré and SST continue to remain blinded to results of the study by treatment group. The Phase 2b RESPOND clinical study is a multi-center, double-blind, placebo-controlled study to evaluate the efficacy and safety of Sildenafil Cream, 3.6% in premenopausal patients with female sexual arousal disorder (FSAD).

Key Points: 
  • The interim analysis was conducted by an independent third-party statistical resource and both Dar and SST continue to remain blinded to results of the study by treatment group.
  • The Phase 2b RESPOND clinical study is a multi-center, double-blind, placebo-controlled study to evaluate the efficacy and safety of Sildenafil Cream, 3.6% in premenopausal patients with female sexual arousal disorder (FSAD).
  • Completing this Phase 2b study will be a significant milestone in the development of what has the potential to be the first FDA-approved product to treat FSAD.
  • FSAD is distinct from hypoactive sexual desire disorder (HSDD) in women, which is characterized primarily by a lack of sexual desire.

Daré Bioscience Reports First Quarter 2022 Financial Results and Provides a Company Update

Retrieved on: 
Thursday, May 12, 2022
Cream, Form, Food, Research, VVA, Review, Pharmacokinetics, Female, Conference, IDE, Sexual arousal disorder, NICHD, Twitter, Social media, Health minister, Woman, Bacterial vaginosis, Clinical trial, Investor, COVID-19, Failure, Quarter, IVR, Progesterone, Fertility, CRADA, GLOBE, Software, Company, Vaginitis, Bacteria, Health, Trial of the century, NIH, FDA, Birth, Tamoxifen, National, Risk, ID, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, NASDAQ, FSAD, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Intellectual property, Forward-looking statement, Human development, Safety, Menopause, Development, 8-K, Online gambling, Birth control, Video game, Pharmaceutical industry, Security (finance), Organon, Bayer

SAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the quarter ended March 31, 2022 and provided a company update.

Key Points: 
  • ET
    SAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) -- DarBioscience, Inc. (NASDAQ: DARE), a leader in womens health innovation, today reported financial results for the quarter ended March 31, 2022 and provided a company update.
  • XACIATO is expected to be commercially available in the U.S. in the fourth quarter of 2022.
  • Financial Highlights for the Quarter ended March 31, 2022
    Cash and cash equivalents: $39.3 million at March 31, 2022, compared to $51.7 million at December 31, 2021.
  • Dar will host a conference call and live webcast today at4:30 p.m. Eastern Timeto review financial results for the quarter ended March 31, 2022 and to provide a company update.

Daré Bioscience Reports Full-Year 2021 Financial Results and Provides a Company Update

Retrieved on: 
Thursday, March 31, 2022
Cream, Risk, Eunice Kennedy Shriver National Institute of Child Health and Human Development, CEO, Software, Novel, Twitter, Intellectual property, GLOBE, Vaginitis, National, FSAD, Bacterial vaginosis, Progesterone, Marketing, Trial of the century, Sexual arousal disorder, Fertility, Health minister, Bacteria, Conference, NICHD, Health, Â, NIH, PDUFA, Development, Female, IDE, Human development, NASDAQ, Form, Investor, Forward-looking statement, ID, Clinical trial, Failure, Review, Menopause, FDA, Social media, Patient, Birth, Company, CRADA, PK, Research, Woman, Safety, COVID-19, 8-K, Birth control, Cryptocurrency, Online gambling, Pharmaceutical industry, Security (finance), Bayer, Organon

ET

Key Points: 
  • ET
    SAN DIEGO, March 31, 2022 (GLOBE NEWSWIRE) -- DarBioscience, Inc. (NASDAQ: DARE), a leader in womens health innovation, today reported financial results for the year ended December 31, 2021 and provided a company update.
  • We made significant progress across the portfolio during 2021 and into the first quarter of 2022, most notably with XACIATO, said Sabrina Martucci Johnson, President and CEO of Dar Bioscience.
  • Dar will host a conference call and live webcast today at4:30 p.m. ETto review financial results for the year ended December 31, 2021 and to provide a company update.
  • Dar Bioscience is a biopharmaceutical company committed to advancing innovative products for womens health.

Global Therapeutics for Women's Health Market to 2026 - Featuring Abbvie, Bayer and Eisai among Others - ResearchAndMarkets.com

Retrieved on: 
Monday, January 17, 2022
Health, Pharmaceutical, Vaginismus, R, Epidemiology, Women's health, Polycystic ovary syndrome, Breast cancer, Ageing, PCOS, Female, Menopause, Health minister, Industry, Therapy, Infertility, Diagnosis, Endometriosis, Cancer, Sexual arousal disorder, Risk, Woman, Medical device, Pharmaceutical industry, Pet, Fine chemical

The "Therapeutics for Women's Health: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Therapeutics for Women's Health: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.
  • This report is an analytical business tool that comprehensively evaluates the global market for women's health therapeutics.
  • The format of the study is organized around the following topics -
    Detailed study around women's diseases, such as endometriosis, postmenopausal osteoporosis, menopause, breast cancer and PCOS.
  • Observations and conclusions regarding the future of market for women's health therapeutics.

Daré Bioscience Reports Third Quarter 2021 Financial Results and Provides a Company Update

Retrieved on: 
Wednesday, November 10, 2021
Cream, NDA, Menopause, Novel, Safety, NICHD, Intellectual property, Form, Fertility, Female, Investor, Health, Clinical trial, Sexual arousal disorder, Health minister, NASDAQ, CEO, National, IDE, 8-K, Failure, Insurance, FSAD, Trial of the century, Progesterone, COVID-19, Social media, Forward-looking statement, Software, ID, Birth, Woman, Twitter, Conference, Company, Research, GLOBE, Development, Bacterial vaginosis, CRADA, PDUFA, Human development, Review, Patient, NIH, Risk, FDA, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Pharmaceutical industry, Animal, Cryptocurrency, Video game

SAN DIEGO, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the quarter ended September 30, 2021 and provided a company update.

Key Points: 
  • ET
    SAN DIEGO, Nov. 10, 2021 (GLOBE NEWSWIRE) -- DarBioscience, Inc. (NASDAQ: DARE), a leader in womens health innovation, today reported financial results for the quarter ended September 30, 2021 and provided a company update.
  • Financial Highlights for period ended September 30, 2021
    Cash and cash equivalents: $45.6 million at September 30, 2021, compared to $4.7 million at December 31, 2020.
  • Dar will host a conference call and live webcast today at4:30 p.m. ETto review the company's financial results for the quarter ended September 30, 2021 and to provide a company update.
  • Dar Bioscience is a clinical-stage biopharmaceutical company committed to advancing innovative products for womens health.

MysteryVibe Latest Study Finds that Vibrators Relieve Menopausal Symptoms including Arousal Disorder and Vaginal Atrophy

Retrieved on: 
Wednesday, October 20, 2021
Erectile dysfunction, Vagina, Pain, Woman, Muscle, Lubrication, Health minister, MysteryVibe, Sexual dysfunction, Personal lubricant, LOS, Vaginal discharge, Sexual arousal disorder, Human, Irritation, Statistics, Vibration, Atrophy, Research, Urology, Internal, Dry, FDA, Quality of life, Pelvic pain, Arousal, Menopause, Patient, Birth control

LOS ANGELES, Oct. 20, 2021 /PRNewswire/ -- Menopause is an inevitable experience for women, and so are the painful symptoms, like vaginal atrophy, vaginal dryness, and arousal disorder that accompany this biological transition. In their case study, sexual wellness company, MysteryVibe, found evidence that supports vibrators as effective therapeutic tools in managing the negative symptoms of menopause.

Key Points: 
  • LOS ANGELES, Oct. 20, 2021 /PRNewswire/ --Menopause is an inevitable experience for women, and so are the painful symptoms, like vaginal atrophy, vaginal dryness, and arousal disorder that accompany this biological transition.
  • In their case study, sexual wellness company, MysteryVibe , found evidence that supports vibrators as effective therapeutic tools in managing the negative symptoms of menopause.
  • The average age of menopause in the United States is 51, and sexual dysfunction in menopausal women is upwards of 86.5%.
  • MysteryVibe creates award-winning medical devices that help address big issues in sexual health like pain, erectile dysfunction & arousal disorder.

MysteryVibe Latest Study Finds that Vibrators Relieve Menopausal Symptoms including Arousal Disorder and Vaginal Atrophy

Retrieved on: 
Wednesday, October 20, 2021
Erectile dysfunction, Vagina, Pain, Woman, Muscle, Lubrication, Health minister, MysteryVibe, Sexual dysfunction, Personal lubricant, Vaginal discharge, Sexual arousal disorder, Human, Irritation, Statistics, Vibration, Atrophy, Multimedia, Research, Urology, Internal, Dry, FDA, Quality of life, Pelvic pain, Arousal, Menopause, Patient, Birth control

LOS ANGELES, Oct. 20, 2021 /PRNewswire/ --Menopause is an inevitable experience for women, and so are the painful symptoms, like vaginal atrophy, vaginal dryness, and arousal disorder that accompany this biological transition.

Key Points: 
  • LOS ANGELES, Oct. 20, 2021 /PRNewswire/ --Menopause is an inevitable experience for women, and so are the painful symptoms, like vaginal atrophy, vaginal dryness, and arousal disorder that accompany this biological transition.
  • In their case study, sexual wellness company, MysteryVibe , found evidence that supports vibrators as effective therapeutic tools in managing the negative symptoms of menopause.
  • The average age of menopause in the United States is 51, and sexual dysfunction in menopausal women is upwards of 86.5%.
  • MysteryVibe creates award-winning medical devices that help address big issues in sexual health like pain, erectile dysfunction & arousal disorder.